Subscribe to Search results

The warning label on Kryobulin by Immuno Ltd stated that despite the precautions taken in the selection and testing of donors and donations, the risk of transmitting hepatitis could not be entirely excluded.

Published on:

Abbott Laboratories Ltd information pages for Antihemophilic Factor (Human) included the warning that "This product is prepared from units of human plasma which have been tested and found nonreactive for Hepatitis Associated Antigen. However, it is recognized that presently available methods are not sensitive enough to detect all units of potential infectious plasma and the risk of transmitting hepatitis is still present."

Published on:

The initial product label for Profilate by Alpha/Abbott Laboratories included a warning which stated that "Patients with mild deficiencies who consequently have not received multiple transfusions of blood, or blood products, are at greatest risk. Under such circumstances, the benefits of Profilate administration must be weighed carefully against the risk of viral hepatitis"

Published on:

Alpha/Abbott Laboratories data sheet and warning label for Profilate later included the statement that present methods of testing plasma were not sensitive enough to detect all units of infective plasma and that whenever possible single donor products were preferable.

Published on:

Abbott Laboratories data sheet for Profilate repeated the warning on the 1976 label that the benefits of administration must be weighed against the risk of viral hepatitis.

Published on:

Alpha's application for the renewal of its license of heat treated profilate contained the warning that viral hepatitis may be transmitted by the product.

Published on:

A study by Kasper and Kipnis reviewed the incidence of clinical hepatitis in people with haemophilia and concluded that older children and adults who had little exposure to blood products were at a high risk of developing hepatitis after the introduction of clotting factor concentrates.

Published on:

Hyland Laboratories product information leaflet for Hemofil contained the warning that although the lot had been reconstituted for use and found non reactive for HBsAg using RIA techniques the product should continue to be considered to carry a risk with respect to hepatitis.

Published on:

Cutter laboratories included a warning on Koate label which stated that "Koate concentrate is a purified dried fraction of pooled plasma obtained from many paid donors. The presence of hepatitis virus should be assumed and the hazard of administering Koate concentrate should be weighed against the medical consequence of withholding it."

Published on:

The warning label on Armour's Factorate package insert stated that radioimmunoassay testing for Hepatitis B surface antigen had been done, however that since no completely reliable laboratory test was yet available to detect all potentially infectious plasma donations, the risk of transmitting viral hepatitis was still present.

Published on:

The wording of the warning label on Armour's Factorate was done in a roundabout way; unlike the more direct approach of some other manufacturers such as Cutter, Armour's said that "Despite careful selection of donors, it may contain causative agents of viral hepatitis."

Published on:

The warning label on Armour's Factorate package continued to state that the risk of transmitting viral hepatitis to patients was still present, and personnel administering this should exercise caution.

Published on:

David Gury at Alpha sent out a series of urgent communications on AIDS on their new donor selection policies which were due to be be given to donors, deferred donors and donor centre personnel.

Published on:

Dr Lane submitted a draft proof of evidence for the HIV Haemophilia Litigation.

Published on:

Dr Lane focused on the view that BPL should be rebuilt. A large investment was required.

Published on:

The Expert Group on the Treatment of Haemophilia had set a goal of 250,000 donations to be used for Factor 8 concentrate (March 1973); this had been increased to 275,000 by regional transfusion directors following the Joint Steering Committee (June and July 1973).

Published on:

Dr Bowley wrote a letter to colleagues seeking to make a case for using better quality cryoprecipitate instead of imported factor concentrates.

Published on:

Dr Biggs wrote to Dr Waiter discussing seeking an increase in the supplies of commercially produced concentrates.

Published on:

By 1976, 46% of donations in Scotland were issued as red cell concentrates. By 1982, 60% of donations were being processed into red cell concentrates with 200ml of plasma removed.

Published on:

A Working Party on Human AHG meeting debated where the preparation of AHG should take place.

Published on: